Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlonstobart with or without SYHA1813 versus placebo consolidation after chemoradiotherapy for limited-stage small cell lung cancer
CTR20251467Phase 3Active
- Sponsor
- Runshi Pharma
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PBI-1308, SYHA1813 in small cell lung cancer (SCLC), sponsored by Runshi Pharma. Started Jun 2025; status: active.
02
Drugs
PBI-1308SYHA1813
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20251467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251467.